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Abstract 
Refractory epilepsy is reportedly associated with an overexpression of ATP-binding cassette 
transporters such as P-glycoprotein (Pgp) and breast cancer resistance protein (Bcrp). In this study, 
we examined the contribution of Pgp and Bcrp to the brain distribution of 12 antiepileptic drugs 
(AEDs) in Mdr1a/1b(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice within a therapeutic concentration range. 
The blood concentrations were sequentially determined, and the brain concentrations were 
measured at 60 min after intravenous administration. The plasma concentration profiles for each 
AED in the Mdr1a/1b(-/-) mice were equivalent to those in the wild-type mice. In contrast, the 
plasma concentration profiles of phenytoin, lamotrigine, topiramate, tiagabine, and levetiracetam in 
the Mdr1a/1b(-/-)/Bcrp(-/-) mice were significantly lower than the corresponding ones in the 
wild-type mice. The brain-to-plasma concentration ratio (Kpbrain) values of phenytoin, topiramate, 
and tiagabine in the Mdr1a/1b(-/-) mice were significantly higher than the corresponding ones in 
the wild-type mice. In contrast, the Kpbrain values of phenobarbital, clobazam, zonisamide, 
gabapentin, tiagabine, and levetiracetam in the Mdr1a/1b(-/-)/Bcrp(-/-) mice were significantly 
higher than the corresponding ones in Mdr1a/1b(-/-) mice. The Kpbrain values of the 12 AEDs in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice, but not wild-type mice, significantly correlated with the 
corresponding molecular weight values. These findings suggest that both Pgp and Bcrp restrict 
brain access for several AEDs. Taken together, information on the contribution of each transporter 
may be useful in the development of strategic treatments of refractory epilepsy. 




Epilepsy is the most prevalent chronic neurological disorder, and it affects at least 50 million 
people worldwide (Kwan et al., 2011). After the 1990s, a new generation of antiepileptic drugs 
(AEDs) emerged and more than 20 AEDs have been clinically used worldwide. The majority of 
epilepsy patients have good control over their seizures with AED use; however, approximately 30% 
of epilepsy patients exhibit refractory epilepsy, which is characterized by uncontrolled seizures, 
despite multiple AED treatments (Gao et al., 2012; Kwan et al., 2010). These epilepsy patients are 
often resistant to a range of AEDs, although these drugs differ from each other in their 
pharmacokinetic properties and mechanisms of action. 
ATP-binding cassette (ABC) transporters, including P-glycoprotein (Pgp; also known as 
Mdr1; Abcb1), multidrug resistance-associated proteins (Mrps; Abccs), and breast cancer resistance 
protein (Bcrp; Abcg2), are transmembrane proteins that function in the disposition of a wide variety 
of drugs (Löscher and Potschka, 2005). Most multidrug ABC transporters have broad and 
substantially overlapping substrate specificities, and their substrates include many drugs and drug 
metabolites (Lagas et al., 2009). It has been hypothesized that the overexpression of ABC 
transporters at the blood-brain barrier (BBB) contributes to drug resistance. The expression of Pgp 
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and Bcrp has been shown to be up-regulated in brain capillary endothelial cells in epilepsy patients 
or animal models of epilepsy (Aronica et al., 2005; Dombrowski et al., 2001; van Vliet et al., 2005). 
The transporter hypothesis is based on the assumption that many or almost all AEDs are substrates 
of ABC transporters. In the recent review (Zang et al., 2012), many AEDs have been classified into 
five categories on the Pgp substrate status combining the evidence of in vitro cell models and in 
vivo animal models or patients. For example, phenytoin and carbamazepine have been widely used 
to treat several types of epilepsy for many decades, and they were suggested to be definite and 
possible substrates for Pgp, respectively (Zhang et al., 2012). Although in vitro evidence on the Pgp 
status of AEDs using the Pgp-expressing cell models was accumulated, evidence from animal 
models is not fully available (Zhang et al., 2012; Löscher et al., 2011). In addition, limited 
information is available regarding the interaction between Bcrp and AEDs (Cerveny et al., 2006). 
The purpose of this study was to assess the effects of Pgp and Bcrp on the brain distribution 
of 12 AEDs in Mdr1a/1b(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice. In this study, we simultaneously 
administered 6 AEDs within a therapeutic concentration range and measured the drug 
concentrations using ultra-performance liquid chromatography combined with tandem mass 
spectrometry (UPLC-MS/MS), which helps evaluate the characteristics of each drug and minimizes 
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the effects of inter-individual variability and experimental errors. 
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2. Materials and Methods 
2.1. Materials 
Carbamazepine, phenobarbital sodium, phenytoin, valproate sodium, and zonisamide were 
purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Ethosuximide, gabapentin, 
topiramate, tiagabine, and levetiracetam were purchased from Toronto Research Chemical Inc. 
(North York, ON, Canada). Lamotrigine was purchased from LKT Laboratories, Inc. (St. Paul, MN, 
USA). Clobazam was a gift from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). All other 
chemicals used were of the highest grade available. The chemical structures of all of the 
investigated AEDs are shown in Fig. 1. 
 
2.2. Animals 
Male Mdr1a/1b(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice obtained from Taconic Farms 
(Germantown, NY, USA) and male wild-type mice of the same genetic background (FVB) obtained 
from CLEA Japan (Yokohama, Japan) between the ages of 9 and 16 weeks were used. The animals 
were anesthetized with isoflurane (inhalation) (anesthesia system of animal; DS Pharma Biomedical. 
Co., Ltd., Osaka, Japan), and the animal experiments were performed in accordance with the 
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Guidelines for Animal Experiments of Kyoto University. 
 
2.3. Pharmacokinetics studies 
The femoral and jugular veins were cannulated with polyethylene tubing for drug 
administration (PE-10; BD Biosciences, San Jose, CA, USA) and blood sampling (SP31; Natsume 
Seisakusho Co. Ltd., Tokyo, Japan), respectively. The 12 AEDs were divided into 2 groups: (1) 
phenytoin (10 mg/kg), carbamazepine (10 mg/kg), gabapentin (10 mg/kg), lamotrigine (3 mg/kg), 
topiramate (10 mg/kg), and levetiracetam (10 mg/kg), and (2) phenobarbital (5 mg/kg), 
ethosuximide (50 mg/kg), valproic acid (50 mg/kg), clobazam (0.5 mg/kg), zonisamide (5 mg/kg), 
and tiagabine (0.5 mg/kg). Each dosage was determined so that the plasma concentrations were 
within the therapeutic range. Each group of AEDs was dissolved in saline containing 10% ethanol 
and 10% Cremophor
®
 EL (Nacalai Tesque, Inc., Kyoto, Japan). The solution for the first group was 
alkalinized for phenytoin. The AEDs-mixture solutions were then intravenously injected at a 
volume of 10 mL/kg via the catheterized femoral vein over 3 min at the beginning of the time 
course. Blood samples (0.05–0.07 mL) were collected from the jugular vein at 5, 10, 15, 30, and 60 
min after the injection. Plasma was immediately separated by centrifugation (20,238 g for 5 min at 
 8 
room temperature), and stored at -20°C until assayed. After 60 min, the whole brain, kidney, and 
liver were removed and homogenized in either an equal (brain) volume of or 4 times (kidney and 
liver) the volume of saline. Homogenized tissues were centrifuged (21,800 g for 5 min at 4°C), and 
the supernatant was stored at -20°C until further assayed. 
The concentrations of the 12 AEDs in the plasma and tissues were measured using 
UPLC-MS/MS (Waters Corporation, Milford, MA, USA) as previously described (Shibata et al., 
2012). 
 
2.4. Data analysis 
The pharmacokinetic parameters, total body clearance (CL), volume of distribution at steady 
state (Vss), and terminal half-life (T1/2 were calculated by non-compartmental analysis with 
WinNonlin
® version 6.0 (Pharsight, Sunnyvale, CA, USA). The tissue distribution of each AED in 
the mice was evaluated using the tissue-to-plasma concentration ratio (Kptissue) at 60 min after 
administration. 
To determine the covariate of Kpbrain, we examined the regression between the Kpbrain values 
in the Mdr1a/1b(-/-)/Bcrp(-/-) mice and the molecular weight (MW) or logarithm of the calculated 
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partition coefficient (cLogP):  
Kpbrain = θ1 + θ2 × cLogP + θ3 × MW
θ4
 
where θ1–θ4 are the mean estimated parameters. The MW and cLogP of the 12 AEDs were 
calculated using ChemDraw
®
 version 12.0 (PerkinElmer Inc., Waltham, MA, USA), and model 
analyses were performed using the nonlinear mixed-effects modeling program NONMEM version 
7.2 (Beal et al., 1992). The effect of the MW and cLogP was examined using the smallest Akaike 
information criterion (AIC) values (Akaike, 1974). 
The values were expressed as means ± S.E. The statistical software package GraphPad Prism
®
 
version 5.0 (GraphPad Software, Inc., San Diego, CA, USA) were used for performing statistical 
analyses. The plasma concentration profiles were compared by repeated measures analysis of 
variance (ANOVA). The statistical differences between the mean values were analyzed using the 
non-paired t-test if the variance was equivalent. If the variance was not equivalent, then the 
Mann-Whitney test was performed. Multiple comparisons were performed using ANOVA followed 
by the Bonferroni test. The Pearson’s correlation coefficient (r) was used to estimate the 
correlations between 2 factors. A value of P < 0.05 was considered to be statistically significant. 
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3. Results 
3.1. Pharmacokinetics of 12 AEDs in the wild-type, Mdr1a/1b(-/-), and Mdr1a/1b(-/-)/Bcrp(-/-) 
mice 
The plasma concentration profiles of all of the 12 AEDs were similar between the 
Mdr1a/1b(-/-) mice and wild-type mice (Fig. 2). In contrast, the plasma concentration profiles of 
phenytoin, lamotrigine, topiramate, tiagabine, and levetiracetam were found to be decreased in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice compared to wild-type mice (Fig. 3). The pharmacokinetic parameters 
of the 12 AEDs in the Mdr1a/1b(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice are summarized in Tables 1 
and 2, respectively. The CL, Vss, and T1/2,of each AED in the Mdr1a/1b(-/-) mice were comparable 
to those in the wild-type mice. In contrast, the CL of zonisamide, gabapentin, and levetiracetam was 
significantly higher in the Mdr1a/1b(-/-)/Bcrp(-/-) mice than in the wild-type mice, and the Vss of 
phenytoin, clobazam, topiramate, and levetiracetam were found to be significantly increased in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice compared to the wild-type mice. The T1/2, zonisamide and 
levetiracetam smaller Mdr1a/1b(-/-)/Bcrp(-/-) mice 
than in the wild-type mice.  
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3.2. Impact of Pgp and Bcrp on AED tissue distribution 
The brain-to-plasma concentration ratio (Kpbrain) values of the 12 AEDs examined at 60 min 
are shown as the percentage of the control (wild-type mice) (Fig. 4). The Kpbrain values of phenytoin, 
topiramate, and tiagabine were found to be significantly increased (1.44-, 1.50-, and 1.31-fold, 
respectively) in the Mdr1a/1b(-/-) mice compared to the wild-type mice. In contrast, the Kpbrain 
values of phenobarbital, clobazam, zonisamide, gabapentin, tiagabine, and levetiracetam were 
significantly higher (1.49-, 1.33-, 1.17-, 1.61-, 1.49-, and 1.28-fold, respectively) in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice than in the Mdr1a/1b(-/-) mice. 
The kidney or liver-to-plasma concentration ratios (Kpkidney and Kpliver, respectively) in the 
Mdr1a/1b(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice are summarized in Tables 1 and 2, respectively. In 
each strain, the Kpliver values for all AEDs were in the range of 0.633–2.36. The Kpliver value of 
gabapentin was found to be significantly decreased in the Mdr1a/1b(-/-) mice, and the Kpliver value 
of lamotrigine was found to be significantly increased in the Mdr1a/1b(-/-)/Bcrp(-/-) mice 
compared to the wild-type mice. The Kpkidney values were in the range of 0.558–2.24, except that of 
gabapentin, which was in the range of 3.27–5.52. In the Mdr1a/1b(-/-) mice, the Kpkidney value of 
valproic acid was significantly decreased. In contrast, compared to the wild-type mice, the 
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Mdr1a/1b(-/-) mice showed significantly increased Kpkidney value of clobazam. Furthermore, in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice, the Kpkidney values of phenytoin, carbamazepine, and topiramate were 
significantly higher, and the Kpkidney value for gabapentin was significantly lower than the 
corresponding values in the wild-type mice. 
 
3.3. Relationship between the Kpbrain value and MW or cLogP 
After using the backward elimination and forward inclusion method, we selected the final 
model using the smallest AIC value in the Mdr1a/1b(-/-)/Bcrp(-/-) mice: 
Kpbrain (Mdr1a/1b(-/-)/Bcrp(-/-) mice) = 0.00304 × MW 
The relationship between the Kpbrain value and MW in the wild-type mice, and the Kpkidney and 
Kpliver values in both strains were also examined, and are shown in Fig. 5. The Kpbrain value in the 
wild-type mice did not correlate with either the MW or cLogP. Furthermore, the Kpkidney value did 
not correlate with either the MW in the Mdr1a/1b(-/-)/Bcrp(-/-) or wild-type mice. However, the 
Kpliver value showed a significant relationship with the MW in both the Mdr1a/1b(-/-)/Bcrp(-/-) and 
wild-type mice. 
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4. Discussion  
Our study demonstrated 2 main findings: (a) Pgp contributed to the limitation of the brain 
distribution of phenytoin, topiramate, and tiagabine, and (b) Bcrp participated in the restriction of 
the brain distribution of phenobarbital, clobazam, zonisamide, gabapentin, tiagabine, and 
levetiracetam.  
In this study, phenytoin, topiramate, and tiagabine proved to be Pgp substrates, and 
ethosuximide, carbamazepine, valproic acid, and lamotrigine were not substrates. A previous in vivo 
study using Mdr1a/1b(-/-) mice showed a 46% increase in hippocampal phenytoin concentrations 
(Rizzi et al., 2002). In the same report, carbamazepine concentrations were measurable in the 
hippocampal in Mdr1a/1b(-/-) mice, whereas they were undetectable in wild-type mice (Rizzi et al., 
2002). In another study, Mdr1a/1b(-/-) mice did not exhibit significantly different brain 
concentrations of carbamazepine after intraperitoneal administration from those in wild-type mice 
(Owen et al., 2001). Thus, phenytoin was evidenced as a Pgp substrate in several reports using in 
vitro and in vivo models, but carbamazepine status for Pgp substrate was controversial (Löscher et 
al., 2011; Zhang et al., 2012). Brain distribution of topiramate was higher in Mdr1a (-/-) mice than 
in wild-type controls (Sills et al., 2002), while ethosuximide was unlikely a Pgp substrate in the 
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Mdr1a/1b (-/-) mouse model (Doran et al., 2005). Therefore, our data were consistent with the 
previous results using in vivo Mdr1 knockout mice for phenytoin, topiramate, and ethosuximide, 
and added the new information on the Pgp-substrate status for tiagabine, valproic acid, and 
lamotrigine.  
In addition, we used Mdr1a/1b(-/-)/Bcrp(-/-) mice to evaluate the Pgp and Bcrp substrate 
status of AEDs. In the mouse BBB, the expression levels of Pgp were the highest of all the 
examined ABC transporters, and Pgp played a pivotal role in drug efflux from the brain (Hartz and 
Bauer, 2010). Moreover, multiple transporter gene knockout mouse models have been commonly 
used to elucidate the synergistic role of Pgp and Bcrp in the efflux of dual substrates at the BBB. 
Although several studies that compared Bcrp(-/-) and wild-type mice failed to demonstrate a 
function of Bcrp in the disposition of topotecan, a substrate of both Pgp and Bcrp, the comparison 
of the Mdr1a/1b(-/-)/Bcrp(-/-) mice and Mdr1a/1b(-/-) mice indicated a contribution of Bcrp to 
topotecan distribution in the brain (de Vries et al., 2007). As illustrated by the recent positron 
emission tomography data of verapamil (Bauer et al., 2012), the Mdr1a/1b(-/-)/Bcrp(-/-) mice 
showed much higher brain levels than would have been expected from data in either Mdr1 or Bcrp 
knockout mice. Therefore, the Mdr1a/1b(-/-)/Bcrp(-/-) mouse model was powerful tool to 
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investigate the synergistic role of Pgp and Bcrp to the brain distribution of AEDs which are both 
Pgp and Bcrp substrates. In our study, we found that the Kpbrain values of phenobarbital, clobazam, 
zonisamide, gabapentin, and levetiracetam increased in the Mdr1a/1b(-/-)/Bcrp(-/-) mice compared 
to the Mdr1a/1b(-/-) mice. Thus, these AEDs are substrates for Bcrp. However, these results may be 
attributable to the cooperative effects of Pgp and Bcrp, and we cannot exclude the potential 
contribution of Pgp to the brain efflux of these 5 AEDs. If we investigated the brain distribution of 
AEDs using Bcrp(-/-) mice, the information on the contribution of Pgp to the brain efflux of these 
AEDs may be obtained.    
To the best of our knowledge, there have been no in vivo reports regarding the involvement of 
Bcrp in the restriction of AED distribution in the brain. The previous in vitro report using human 
Bcrp-expressing Madin-Darby canine kidney cells showed a lack of interaction between Bcrp and 
phenytoin, phenobarbital, ethosuximide, carbamazepine, valproic acid, and lamotrigine (Cerveny et 
al., 2006). In this study, the Kpbrain value of phenobarbital was found to be significantly increased in 
the Mdr1a/1b(-/-)/Bcrp(-/-) mice compared to the Mdr1a/1b(-/-) mice (Fig. 4A), which was 
inconsistent with the result of a previous study (Cerveny et al., 2006). This discrepancy may be due 
to the differences in the in vitro experimental conditions or in species. This is exemplified in cells 
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that express human or mouse Pgp, where there are species differences in AED transport (Baltes et 
al., 2007). Since it is difficult to directly assess the drug distribution in the human brain, a 
combination of in vitro and in vivo data is important to predict AED brain access in humans. The 
plasma concentration profiles in phenytoin, lamotrigine, topiramate, tiagabine, and levetiracetam 
were found to be decreased in the Mdr1a/1b(-/-)/Bcrp(-/-) mice compared to the wild-type mice 
(Fig. 3). These alterations may be because of the restriction of drug distribution by both Pgp and 
Bcrp in the brain and/or other elimination organs. 
There was a significant difference between the Kpbrain values of phenytoin in the wild-type 
and Mdr1a/1b(-/-) mice; however, there were no significant differences between the Kpbrain values 
of phenytoin in the wild-type and Mdr1a/1b(-/-)/Bcrp(-/-) mice (Fig. 4B). This discrepancy may be 
due to an experimental error; however, potential compensatory effects in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice should not be discounted. Namely, the expression of other transporters 
may be affected and consequently mask the genuine effects of Pgp or Bcrp. Phenytoin has been 
reported to be transported by Mrp2 (Potschka et al., 2003). Thus, the present results might be 
explained by the functional enhancement and/or increased expression level of Mrp2 at the BBB in 
the Mdr1a/1b(-/-)/Bcrp(-/-) mice, although a recent study using a quantitative proteomics approach 
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showed no compensatory changes in the BBB expression of several transporters (i.e., Pgp, Bcrp, 
and Mrps) in Mdr1a/1b(-/-), Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice (Agarwal et al., 2012). 
We found that the Kpbrain values in the Mdr1a/1b(-/-)/Bcrp(-/-) mice significantly correlated 
with the MW values, and the Kpliver values also significantly correlated with the MW values in both 
the Mdr1a/1b(-/-)/Bcrp(-/-) and wild-type mice. However, no correlation was observed between the 
Kpbrain and MW values in the wild-type mice. Since the Kpliver values of nearly all AEDs were 
unaffected in the Mdr1a/1b(-/-)/Bcrp(-/-) mice, the effects of Pgp and Bcrp on the liver distribution 
of many AEDs were considered to be negligible, and the distribution of the 12 AEDs were predicted 
from their MW values. Further, in case of a lack of contribution from Pgp and Bcrp at the BBB, 
brain distribution of many AEDs would depend on their MW values. Therefore, of the several ABC 
transporters in the BBB, Pgp and Bcrp appear to play a pivotal role in the efflux of AEDs from the 
brain. Since the observed Kpbrain values of phenytoin and valproic acid were relatively lower than 
their predicted values, other efflux transporters might also affect the distribution of these AEDs in 
the brain (Fig. 5A). Furthermore, since the observed Kpbrain values of ethosuximide, clobazam, and 
zonisamide were higher than their predicted values, these AEDs exhibited several properties that 
enabled effective distribution in the brain. 
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The Kpbrain value of each AED in the Mdr1a/1b(-/-)/Bcrp(-/-) mice was at most 2-fold higher 
than that in the wild-type mice, which indicated that Pgp and Bcrp played a relatively minor role in 
the efflux of AEDs from the brain (Fig. 4). However, Pgp and Bcrp may have vital clinical roles, 
because these transporters were overexpressed in patients with refractory epilepsy (Aronica et al., 
2005; Dombrowski et al., 2001). This is also supported by the higher expression levels of Bcrp in 
the human brain capillary endothelial cells than in mice (Uchida et al., 2011). Considering the 
effects of brain efflux transporters at the human BBB, information on the substrate status of Bcrp is 
valuable. Thus, additional clinical research is required to determine the proper selection of AEDs 
for the treatment of refractory epilepsy. 
Our study had some restrictions that should be discussed. Since 6 AEDs were injected 
simultaneously, some pharmacokinetic drug-drug interactions might occur and affect the Pgp and 
Bcrp status of each AED. However, since combined AEDs are general in the treatment of refractory 
epilepsy, it is meaningful to investigate the brain distribution of each drug after the simultaneous 
administration in the therapeutic ranges. On one hand, Pgp-mediated transport was reported to 
highly depend on the AED concentrations (Löscher et al., 2011). Each AED was used at only one 
dose in this study, which may lead to false negative results. We tried to investigate the interaction of 
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AEDs with Pgp or Bcrp in the therapeutic concentration range in humans, but the concentrations of 
zonisamide and lamotrigine were below the therapeutic range, and that of tiagabine was above the 
range (Figs. 2 and 3). Our data showed that zonisamide was interacted with Bcrp, and that tigabine 
was interacted with both Pgp and Bcrp. On one hand, Pgp or Bcrp-mediated brain distribution of 
lamotrigine was not apparent, although the plasma concentration profile of lamotrigine in the 
Mdr1a/1b(-/-)/Bcrp(-/-) mice were significantly lower than that in the wild-type mice. Brain access 
of lamotrigine was limited by Pgp in the in vivo brain microdialysis study in rats (Potschka et al., 
2002). Since plasma concentrations of lamotrigine in their study were 2-fold higher than those in 
the present study, Pgp-mediated interaction may be identified if higher concentrations were used. In 
addition, only the whole brain was analysed at only one time point (60 min after the intravenous 
administration) in this study, which may lead to false negative results for the Pgp transport. More 
precise studies using the brain fraction and time course data were needed in the future 
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5. Conclusion 
Taken together, the findings of the present study indicate that both Pgp and Bcrp significantly 
affect the brain distribution of several AEDs. Studies evaluating the contribution of each transporter 
may be useful in the development of strategic treatments of refractory epilepsy. 
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Fig. 1. Chemical structures of the 12 antiepileptic drugs. 
 
Fig. 2. The plasma concentration profiles of the 12 antiepileptic drugs in wild-type and 
Mdr1a/1b(-/-) mice. Each point represents the mean ± S.E. (n = 4–6). The plasma concentrations in 
Mdr1a/1b(-/-) mice (filled circle) were compared with those in wild-type mice (open circle) by 
using repeated measures ANOVA.  
 
Fig. 3. The plasma concentration profiles of the 12 antiepileptic drugs in wild-type and 
Mdr1a/1b(-/-)/Bcrp(-/-) mice. Each point represents the mean ± S.E. (n = 5–6). The plasma 
concentrations in Mdr1a/1b(-/-)/Bcrp(-/-) mice (filled circle) were compared with those in wild-type 
mice (open circle) by using repeated measures ANOVA, *P < 0.05, **P < 0.01, ***P < 0.005. 
 
Fig. 4. Changes in the brain-to-plasma concentration ratio (Kpbrain) values for the 12 antiepileptic 
drugs in wild-type, Mdr1a/1b(-/-), and Mdr1a/1b(-/-)/Bcrp(-/-) mice at 60 min after administration. 
Each bar represents the mean ± S.E. (n = 5–11). Each Kpbrain value in the knockout mice was 
divided by the mean Kpbrain value of the corresponding control (wild-type mice). The mean ± S.E. 
value of the wild-type mice (n = 10–11) were as follows: phenobarbital, 0.734 ± 0.109; phenytoin, 
0.371 ± 0.026; ethosuximide, 0.798 ± 0.065; carbamazepine, 0.748 ± 0.042; valproic acid, 0.181 ± 
0.012; clobazam, 0.866 ± 0.047; zonisamide, 1.12 ± 0.04; lamotrigine, 0.690 ± 0.045; gabapentin, 
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0.432 ± 0.050; topiramate, 0.585 ± 0.023; tiagabine, 0.681 ± 0.047; and levetiracetam, 0.495 ± 
0.045. Statistical analyses were performed using ANOVA followed by the Bonferroni test, *P < 0.05, 
**P < 0.01, ***P < 0.005. 
 
Fig. 5. The relationship between the molecular weight (MW) and brain, kidney or liver-to-plasma 
concentration ratio (Kpbrain, Kpkidney, or Kpliver) values of the 12 antiepileptic drugs in wild-type and 
Mdr1a/1b(-/-)/Bcrp(-/-) mice. The observed Kpbrain, Kpkidney, and Kpliver values in the wild-type 
mice (open circle) and Mdr1a/1b(-/-)/Bcrp(-/-) mice (filled circle) are shown as the mean values (n 
= 5–6). A: The solid line represents the final model for the Kpbrain value in Mdr1a/1b(-/-)/Bcrp(-/-) 
mice: Kpbrain (Mdr1a/1b(-/-)/Bcrp(-/-) mice) = 0.00304 × MW, r
2
 = 0.457, P < 0.0001, and the 
dashed line represents the correlation between the Kpbrain value and MW in wild-type mice: Kpbrain 
(wild-type mice) = 0.000837 × MW + 0.356, r
2
 = 0.0706, P = 0.404. B: The solid line represents the 
correlation between the Kpkidney value and MW in Mdr1a/1b(-/-)/Bcrp(-/-) mice: Kpkidney 
(Mdr1a/1b(-/-)/Bcrp(-/-) mice) = -0.00139 × MW + 1.81, r
2
 = 0.0239, P = 0.631, and the dashed 
line represents the correlation between the Kpkidney and MW in wild-type mice: Kpkidney (wild-type 
mice) = -0.00386 × MW + 2.48, r
2
 = 0.0493, P = 0.488. C: The solid line represents the correlation 
between the Kpliver value and MW in Mdr1a/1b(-/-)/Bcrp(-/-) mice: Kpliver (Mdr1a/1b(-/-)/Bcrp(-/-) 
mice) = 0.00524 × MW, r
2
 = 0.617, P < 0.0001, and the dashed line represents the correlation 
between Kpliver and MW in wild-type mice: Kpliver (wild-type mice) = 0.00484 × MW, r
2
 = 0.573, P 
< 0.0001.  
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PB: phenobarbital, PHT: phenytoin, ESM: ethosuximide, CBZ: carbamazepine, VPA: valproic acid, 
CLB: clobazam, ZNS: zonisamide, LTG: lamotrigine, GBP: gabapentin, TPM: topiramate, TGB: 
tiagabine, LVT: levetiracetam 
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Table 1 Pharmacokinetic parameters, Kpkidney, and Kpliver of 12 AEDs in wild-type and Mdr1a/1b(-/-) mice 
 CL (mL/min/kg)  Vss (mL/kg)  T1/2(min)  Kpkidney  Kpliver 
 Wild-type  Mdr1a/1b(-/-)   Wild-type  Mdr1a/1b(-/-)   Wild-type Mdr1a/1b(-/-)  Wild-type Mdr1a/1b(-/-)   Wild-type Mdr1a/1b(-/-)  
Phenobarbital 3.83 ± 0.60 4.25 ± 1.16  625 ± 36 634 ± 27  142 ± 40 248 ± 146  1.23 ± 0.06  1.20 ± 0.15   1.48 ± 0.19  1.56 ± 0.061  
Phenytoin 3.86 ± 0.48 2.98 ± 0.84  1063 ± 62 1136 ± 16  209 ± 43 396 ± 179  0.693 ± 0.040  0.749 ± 0.049   1.39 ± 0.15 1.25 ± 0.10 
Ethosuximide 2.99 ± 0.63 3.24 ± 0.74  555 ± 45 568 ± 47  159 ± 34 172 ± 56  0.915 ± 0.050  1.01 ± 0.11   0.934 ± 0.113  0.960 ± 0.083  
Carbamazepine 8.16 ± 0.88 8.33 ± 0.83  1482 ± 65 1602 ± 48  136 ± 19 141 ± 15  1.27 ± 0.05 1.38 ± 0.07  1.98 ± 0.10 1.81 ± 0.04 
Valproic acid 2.83 ± 0.43 3.25 ± 0.60  375 ± 10 375 ± 18  108 ± 22 97 ± 20  2.24 ± 0.36  1.21 ± 0.16*  0.899 ± 0.057  0.937 ± 0.091  
Clobazam 44.4 ± 2.5 45.2 ± 3.0  1752 ± 80 1837 ± 94  29.5 ± 1.4 29.5 ± 0.9  1.37 ± 0.19  1.88 ± 0.10*  2.05 ± 0.09  1.96 ± 0.14  
Zonisamide 5.54 ± 0.46 5.71 ± 0.87  1136 ± 74 1130 ± 93  145 ± 10 147 ± 16  1.70 ± 0.07  1.64 ± 0.10   n.d. 
Lamotrigine 5.04 ± 0.38 5.42 ± 0.59  1266 ± 49 1324 ± 32  200 ± 28 187 ± 25  1.94 ± 0.06 2.15 ± 0.14   1.69 ± 0.12  1.57 ± 0.05  
Gabapentin 12.6 ± 2.1 9.15 ± 2.06  802 ± 42 845 ± 54  52.5 ± 11.9 84.1 ± 23.5  5.29 ± 1.14 4.29 ± 0.27  1.12 ± 0.03 1.00 ± 0.02**  
Topiramate 4.67 ± 0.77 4.22 ± 0.41  846 ± 41 875 ± 17  144 ± 32 152 ± 16  1.21 ± 0.04 1.23 ± 0.04  1.18 ± 0.04 1.12 ± 0.02  
Tiagabine 17.5 ± 0.7 18.3 ± 1.7  1308 ± 53 1305 ± 75  52.4 ± 1.0 51.0 ± 3.4  0.602 ± 0.136  0.969 ± 0.171   2.36 ± 0.25  2.26 ± 0.33  
Levetiracetam 4.04 ± 0.91 3.10 ± 0.75  658 ± 23 696 ± 21  136 ± 37 216 ± 66  1.31 ± 0.15 1.28 ± 0.04  0.825 ± 0.078  0.806 ± 0.034  
Each value represents the mean ± S.E. for 5 or 6 mice. 
CL: clearance, Vss: volume of distribution at steady state, T1/2: terminal half-life,  
Kpkidney: kidney-to-plasma concentration ratio, Kpliver: liver-to-plasma concentration ratio 
*P < 0.05, **P < 0.01, n.d.: not detected 
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Table 2 Pharmacokinetic parameters, Kpkidney, and Kpliver of 12 AEDs in wild-type and Mdr1a/1b(-/-)/Bcrp(-/-) mice 




 Wild-type  
Mdr1a/1b(-/-)/ 
Bcrp(-/-)  
 Wild-type  
Mdr1a/1b(-/-)/ 
Bcrp(-/-)  
 Wild-type  
Mdr1a/1b(-/-)/ 
Bcrp(-/-)  
 Wild-type  
Mdr1a/1b(-/-)/ 
Bcrp(-/-)  
Phenobarbital 2.42 ± 0.78 3.22 ± 1.57  720 ± 65 763 ± 30  1001 ± 858 564 ± 356  1.36 ± 0.19 1.41 ± 0.16  1.44 ± 0.21 1.39 ± 0.11 
Phenytoin 4.80 ± 0.70 3.82 ± 0.74  901 ± 26 1008 ± 20*  141 ± 19 218 ± 54  0.558 ± 0.028 0.694 ± 0.052*  1.03 ± 0.07 1.16 ± 0.10 
Ethosuximide 3.06 ± 0.59 3.44 ± 1.06  681 ± 50 720 ± 57  196 ± 61 196 ± 62  1.14 ± 0.05 0.956 ± 0.18  0.789 ± 0.101 0.904 ± 0.139 
Carbamazepine 6.48 ± 1.23 6.00 ± 0.68  1403 ± 55 1441 ± 43  169 ± 27 172 ± 15  0.734 ± 0.046 1.07 ± 0.06**  1.39 ± 0.08 1.49 ± 0.11 
Valproic acid 3.79 ± 0.34 4.38 ± 0.86  391 ± 22 412 ± 23  75.3 ± 11.5 93.1 ± 39.0  1.28 ± 0.11 1.67 ± 0.27  0.909 ± 0.031 0.967 ± 0.107 
Clobazam 39.7 ± 1.9 38.9 ± 9.4  1925 ± 97 2212 ± 48*  35.7 ± 2.7 117 ± 83  1.57 ± 0.10 1.69 ± 0.06  1.67 ± 0.10 1.85 ± 0.11 
Zonisamide 3.20 ± 0.32 7.45 ± 1.89**  1139 ± 32 1105 ± 30  259 ± 27 122 ± 21**  1.69 ± 0.06 1.68 ± 0.03  n. d. 
Lamotrigine 5.82 ± 0.35 6.42 ± 0.45  1026 ± 40 1149 ± 8  124 ± 9 126 ± 9  1.76 ± 0.12 1.90 ± 0.05  1.09 ± 0.03 1.29 ± 0.09* 
Gabapentin 4.14 ± 0.79 9.06 ± 1.75*  610 ± 46 720 ± 58  118 ± 22 74.1 ± 20.1  5.52 ± 0.72 3.27 ± 0.35*  0.941 ± 0.016 0.943 ± 0.024 
Topiramate 4.30 ± 0.37 4.57 ± 0.28  735 ± 26 817 ± 19*  123 ± 12 126 ± 8  1.12 ± 0.03 1.20 ± 0.02*  1.14 ± 0.05 1.18 ± 0.02 
Tiagabine 11.9 ± 0.7 15.5 ± 2.6  1382 ± 83 1563 ± 72  82.2 ± 7.8 83.2 ± 22.8  1.29 ± 0.10 1.39 ± 0.08  1.89 ± 0.17 2.11 ± 0.15 
Levetiracetam 1.57 ± 0.21 3.48 ± 0.53*  477 ± 18 543 ± 19*  230 ± 36 124 ± 26*  0.795 ± 0.045 0.931 ± 0.066  0.636 ± 0.023 0.633 ± 0.006 
Each value represents the mean ± S.E. for 5 or 6 mice. 
CL: clearance, Vss: volume of distribution at steady state, T1/2: terminal half-life,  
Kpkidney: kidney-to-plasma concentration ratio, Kpliver: liver-to-plasma concentration ratio 
*P < 0.05, **P < 0.01, n.d.: not detected 
 

  
 
 
 
 
